Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Einstein (Sao Paulo). 2023 Oct 27;21:eAO0307. doi: 10.31744/einstein_journal/2023AO0307. eCollection 2023.
To describe the radiological characteristics of hepatocellular carcinoma (HCC) lesions that achieved a complete response following drug-eluting bead transarterial chemoembolization (DEB-TACE) preceding liver transplantation.
This single-center case-control study enrolled patients with hepatocellular carcinoma who underwent neoadjuvant DEB-TACE therapy, were followed up with contrast-enhanced magnetic resonance imaging or computed tomography, and were successively evaluated according to the modified Response Evaluation Criteria in Solid Tumors. The HCCs were divided into two groups based on their diameter (Group A: ≤3cm; Group B: 3cm). Viability was assessed using the Kaplan-Meier method according to tumor size categories. The relationship between tumor variables was analyzed using bivariate Cox regression.
Three-hundred and twenty-eight patients with 667 hepatocellular carcinomas who underwent their first DEB-TACE session were enrolled. A total of 105 hepatocellular carcinomas in 59 patients exhibited complete response after the initial DEB-TACE session and were divided into Group A (92 HCCs) and Group B (13 HCCs). The diameter in Group A decreased significantly compared to the pre-procedure size until the second assessment (p<0.001), with no subsequent reduction in diameter, despite maintaining a complete response. In Group B, the reduction in diameter remained significant compared with the initial value until the sixth imaging evaluation (p=0.014). The average reduction was 45.1% for Group B and a maximum of 14.9% in Group A.
HCCs >3cm exhibited a greater reduction in size and a longer time to recurrence. HCCs ≤3cm had a shorter relapse time. The recurrence rates were similar. These findings may aid in planning for liver transplantation.
描述经载药微球动脉化疗栓塞术(DEB-TACE)治疗后完全缓解的肝细胞癌(HCC)病变的影像学特征,这些病变在肝移植前发生。
本单中心病例对照研究纳入了接受新辅助 DEB-TACE 治疗的肝细胞癌患者,对其进行了对比增强磁共振成像或计算机断层扫描随访,并根据实体瘤反应评估标准(mRECIST)进行了连续评估。根据肿瘤直径将 HCC 分为两组(A 组:≤3cm;B 组:3cm)。根据肿瘤大小类别,采用 Kaplan-Meier 法评估肿瘤活性。采用双变量 Cox 回归分析肿瘤变量之间的关系。
共纳入 328 例患者的 667 个 HCC,这些患者均接受了首次 DEB-TACE 治疗。59 例患者的 105 个 HCC 在初始 DEB-TACE 治疗后表现出完全缓解,分为 A 组(92 个 HCC)和 B 组(13 个 HCC)。A 组的直径与术前相比显著减小,直至第二次评估(p<0.001),尽管仍保持完全缓解,但此后直径没有进一步减小。B 组的直径与初始值相比持续减小,直至第六次影像学评估(p=0.014)。B 组的平均减小幅度为 45.1%,而 A 组最大为 14.9%。
直径>3cm 的 HCC 体积缩小更明显,复发时间更长。直径≤3cm 的 HCC 复发时间更短。复发率相似。这些发现可能有助于肝移植的规划。